Product Pipeline

Flag develops anti-infectious and anti-cancer mRNA vaccines with proprietary structures of mRNAs encoding immune adjuvant, adjuvant/antigen complexes and methods of use.

Flag’s pipeline includes enhanced anti-flu, anti-SARS-CoV-2 mRNA vaccines and vaccines against cancer-associated antigens, such as mutant Tp53 and proteins encoded by LINE-1 retrotransposons.

Flag partners with experts in mRNA formulation technologies to explore its mRNA adjuvants in the contexts of mRNA vaccines with alternative delivery routes.